Stonebridge Capital Advisors’s West Pharmaceutical WST Stock Holding History

Stonebridge Capital Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35	Closed	-$13.1K	–	874
2023 Q3	$13.1K	Hold	35	–	–	﹤0.01%	567
2023 Q2	$13.4K	Buy	35 +30	+600%	+$10.7K	﹤0.01%	574
2023 Q1	$1.73K	Hold	5	–	–	﹤0.01%	822
2022 Q4	$1.18K	Sell	5 -54	-92%	-$12.8K	﹤0.01%	854
2022 Q3	$15K	Buy	59 +4	+7%	+$1.22K	﹤0.01%	512
2022 Q2	$17K	Hold	55	–	–	﹤0.01%	520
2022 Q1	$23K	Hold	55	–	–	﹤0.01%	518
2021 Q4	$26K	Hold	55	–	–	﹤0.01%	473
2021 Q3	$23K	Buy	55 +50	+1,000%	+$21.1K	﹤0.01%	469
2021 Q2	$2K	Hold	5	–	–	﹤0.01%	826
2021 Q1	$1K	Buy	+5	New	+$1.43K	﹤0.01%	942
2020 Q3	–	Sell	-5	Closed	-$1K	–	719
2020 Q2	$1K	Hold	5	–	–	﹤0.01%	757
2020 Q1	$1K	Hold	5	–	–	﹤0.01%	751
2019 Q4	$1K	Hold	5	–	–	﹤0.01%	825
2019 Q3	$1K	Hold	5	–	–	﹤0.01%	836
2019 Q2	$1K	Buy	+5	New	+$590	﹤0.01%	878

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Stonebridge Capital Advisors's WST Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 35 shares — an estimated $13.1K sold.

Stonebridge Capital Advisors first reported a position in WST in Q2 2019 and held it in 16 quarters. The position peaked at $26K in Q4 2021. 783 funds tracked by Wall St. Rank hold WST as of Q4 2023.

Stonebridge Capital Advisors reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 35 West Pharmaceutical shares in Q4 2023, an estimated $13.1K.
Stonebridge Capital Advisors first reported a position in West Pharmaceutical in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's West Pharmaceutical position peaked at $26K in Q4 2021.
783 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.